Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Vorinostat in Advanced Renal, Urothelial, or Prostate Cancer
NCT02619253Phase 1Completed
- Start
- Feb 2016
- Primary completion
- Mar 2023
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of vorinostat in renal cell carcinoma (RCC), urothelial carcinoma (UC) and prostate cancer (PCa) (2 cohorts). Primary endpoints: Objective Response Rate up to 4.5 years and Progression Free Survival up to 4.5 years. Started Feb 2016; status: completed.
02
Drugs
vorinostat
03
Conditions
renal cell carcinoma (RCC)urothelial carcinoma (UC)prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02619253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02619253.